Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Abpro Bio Co., Ltd.
  6. News
  7. Summary
    A195990   KR7195990007

ABPRO BIO CO., LTD.

(A195990)
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment Arm

06/16/2021 EST

Abpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.


ę S&P Capital IQ 2021
All news about ABPRO BIO CO., LTD.
2022Abpro Bio Co., Ltd. (KOSDAQ:A195990) cancelled the acquisiti..
CI
2022Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.91..
CI
2021Abpro Bio Co., Ltd. announced that it has received KRW 5.999999552 billion in funding
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 4.99999895 billion in fund..
CI
2021Abpro Bio Co., Ltd. announced that it has received KRW 15 billion in funding from Merit..
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from..
CI
2020KUKBO Logistics Co.,Ltd acquired 19.35% stake in Bog International Co., Ltd. from Abpro..
CI
2020Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 16.4999812 billion in ..
CI
2020Abpro Bio Co., Ltd. announced that it has received KRW 10 billion in funding from Korea..
CI
2020Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 16.4999812 billi..
CI
More news
Financials
Sales 2021 32 914 M 26,5 M 26,5 M
Net income 2021 -10 030 M -8,07 M -8,07 M
Net cash 2021 32 581 M 26,2 M 26,2 M
P/E ratio 2021 -22,3x
Yield 2021 -
Capitalization 122 B 98,4 M 98,4 M
EV / Sales 2020 8,97x
EV / Sales 2021 6,42x
Nbr of Employees -
Free-Float 90,5%
Chart ABPRO BIO CO., LTD.
Duration : Period :
Abpro Bio Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABPRO BIO CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Pui Chan Ian Yan Co-Chief Executive Officer & Director
Jin-Sang Yang Co-Chief Executive Officer & Director
Jae-Hong Jeon Independent Director
Gab-Jin Kang Independent Director
Ki-Chul An Independent Director